secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001193125-23-292080
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Phase 1 TCR-T data: 6/6 patients achieve complete donor chimerism and MRD negativity; 0/4 controls
--------------------------------------------------------------------------------

- All 6 evaluable patients treated with TSC-100 or TSC-101 achieved complete donor chimerism and MRD negativity; none of 4 control-arm patients achieved these endpoints.
- One AML patient MRD-positive post-HCT converted to MRD-negative after TSC-101 treatment.
- Control arm: one TP53-mutated MDS patient relapsed at ~6 months; two others had worsening chimerism requiring clinical intervention.
- Dose escalation reached third and final level with no dose-limiting toxicities; recommended Phase 2 dose expected from this level.
- Company hosting virtual KOL event Dec 11 to discuss data; 10 clinical sites active with expansion cohorts planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523292080/0001193125-23-292080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312523292080/d840458d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-292080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer